Saturday 17 October 2026 Export QTRX’s income statement to Excel — free account

Quanterix Corporation

Quanterix Corporation’s revenue for fiscal 2025 (year ended December 2025) was $138.9 million, up 1.07% from fiscal 2024. In the quarter to June 2026, revenue grew 34.4%, EPS fell 35.1% and free cash flow grew 18.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

2.87 0.20 −6.51%

Follow QTRX

Alert me

Market cap: $145.2M
P/E: 0.0×
Fwd P/E: −2.6×
Dividend yield: —
F-score: 3/9
Altman Z: −0.87
Beneish M: −0.69
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.30

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	1	—	—	1	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 11.48%

Capital & Financial Ratios $m

Market Cap 145.19

Revenue 153.41

Net Income (123.11)

Free Cash Flow (81.68)

Net Debt (93.53)

Current Ratio 3.40

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (2.57)

P/S ratio 0.88

P/B ratio 0.57

Past 5Y EPS Growth —

This Y EPS Growth 10.69%

Next Y EPS Growth 44.84%

Next Y revenue growth 3.24%

Next 5Y EPS Growth 25.85%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.31%

10-year low 10-year high

P/B against its own 10 years 3.44%

10-year low 10-year high

EV/Sales against its own 10 years 5.24%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	321	289	118	94
Receivables	25	32	30	22
Inventory	26	33	55	48
Other	—	—	—	—
	382	364	212	171

	2023	2024	2025	Q'26
Payables	5	7	14	9
ST’ Debt	—	—	—	—
Other	—	—	—	—
	39	42	75	50

Compound Annual Growth %

	10y	5y	3y
Sales	27.56%	9.97%	9.59%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	7.49%	(6.16%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	36	33	—	—	—
’25	30	24	40	44	139
’24	32	34	36	35	137
’23	28	31	32	32	122
’22	30	24	27	26	106
’21	27	25	28	30	111
’20	16	13	31	26	86

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(18)	(5)	—	—	—
’25	(14)	(6)	(41)	(16)	(77)
’24	(20)	(5)	(6)	(4)	(35)
’23	(10)	1	(4)	(6)	(19)
’22	(22)	(8)	(15)	(4)	(49)
’21	(14)	(10)	(14)	(10)	(48)
’20	(13)	(7)	(7)	5	(23)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(18)	(5)	—	—	—
’25	(15)	(6)	(42)	(16)	(80)
’24	(21)	(7)	(7)	(5)	(39)
’23	(10)	0	(5)	(8)	(23)
’22	(23)	(13)	(18)	(6)	(60)
’21	(14)	(17)	(18)	(13)	(61)
’20	(14)	(8)	(8)	3	(27)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.37)	(1.04)	—	—	—
’25	(0.53)	(0.77)	(0.73)	(0.49)	(2.51)
’24	(0.26)	(0.19)	(0.22)	(0.30)	(1.00)
’23	(0.16)	(0.16)	(0.21)	(0.23)	(0.86)
’22	(0.49)	(0.67)	(0.95)	(0.50)	(2.61)
’21	(0.29)	(0.33)	(0.43)	(0.55)	(1.60)
’20	(0.39)	(0.42)	0.07	(0.31)	(1.10)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	15.56	13.00	17.08	10.90	35.02	6.31	10.02	9.87	4.05	Analyst estimates 2026–2028 Powerpack
	High	—	23.70	24.81	36.15	52.75	92.57	43.32	28.78	29.70	12.41
People
People	Employees	122	126	177	248	314	460	125	441	471	450
	Revenue/emp, $m	0.14	0.18	0.21	0.23	0.28	0.24	0.84	0.28	0.29	0.31
Income, $m
Income, $m	Revenue	18	23	38	57	86	111	106	122	137	139
	Gross margin, %	44.06	43.66	47.69	47.30	55.78	58.59	42.99	60.66	60.47	46.77
	EBT	(23)	(27)	(32)	(41)	(32)	(56)	(99)	(28)	(38)	(112)
	EBT margin, %	(131.78)	(118.12)	(83.73)	(72.24)	(36.94)	(50.28)	(94.21)	(22.58)	(27.72)	(80.83)
	Net income	(23)	(27)	(32)	(41)	(32)	(56)	(100)	(28)	(39)	(107)
	Depreciation	0	0	1	4	5	5	5	8	6	24
Per share, $
Per share, $	Revenue	8.21	6.09	1.71	2.26	2.92	3.07	2.85	3.26	3.58	3.26
	Earnings	(10.81)	(8.30)	(1.43)	(1.63)	(1.10)	(1.60)	(2.61)	(0.86)	(1.00)	(2.51)
	Cash flow	(8.28)	(5.88)	(1.31)	(1.04)	(0.79)	(1.32)	(1.31)	(0.50)	(0.92)	(1.81)
	Capex	(0.25)	(0.30)	(0.07)	(0.43)	(0.13)	(0.38)	(0.31)	(0.10)	(0.09)	(0.06)
	Free cash flow	(8.52)	(6.19)	(1.37)	(1.48)	(0.92)	(1.70)	(1.63)	(0.60)	(1.00)	(1.87)
	Book value	6.29	17.53	1.87	5.13	6.97	12.25	9.68	9.31	8.60	6.94
	Shares, m	2	4	22	25	30	36	37	38	38	43
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	6.61	10.70	10.45	15.93	13.81	4.51	8.34	2.97	1.95
	P/B	0.00	2.30	9.81	4.61	6.68	3.46	1.33	2.92	1.24	0.92
	EV/Sales	0.00	3.54	9.93	8.66	14.17	10.42	1.71	6.04	1.16	1.12
	EV/FCF	(0.65)	(3.48)	(12.36)	(13.27)	(44.84)	(18.80)	(2.99)	(32.60)	(4.13)	(1.95)
Cash, $m
Cash, $m	Operating cash flow	(18)	(22)	(29)	(26)	(23)	(48)	(49)	(19)	(35)	(77)
	Capex	(1)	(1)	(2)	(11)	(4)	(14)	(12)	(4)	(3)	(3)
	Free cash flow	(18)	(23)	(30)	(37)	(27)	(61)	(60)	(23)	(39)	(80)
Balance, $m
Balance, $m	Working capital	24	70	41	113	180	412	350	343	322	137
	Total debt	10	9	8	8	8	22	44	—	—	—
	Net debt	(19)	(70)	(37)	(101)	(174)	(396)	(339)	(321)	(289)	(118)
	Shareholders’ equity	13	66	41	129	206	441	358	350	330	296
Returns, %
Returns, %	ROA	(124.22)	(48.39)	(39.57)	(34.35)	(14.30)	(14.38)	(21.30)	(6.58)	(9.23)	(25.97)
	ROIC	0.00	0.00	(462.99)	(95.71)	(61.28)	(79.41)	(339.54)	(100.39)	(80.37)	(44.21)
	ROE	27.11	126.67	(58.98)	(48.07)	(18.84)	(17.17)	(24.93)	(8.01)	(11.33)	(34.25)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RXST RxSight, Inc.	$194.2M	— (loss-making)	— (loss-making)	+0.31% (above 0%: growing)	n/m	−94.39% (below 0%: shrinking)	76.72%	(40.81%)	Compare
INGN Inogen, Inc	$167.1M	— (loss-making)	— (loss-making)	+3.04% (above 0%: growing)	n/m	−51.15% (below 0%: shrinking)	45.51%	(5.36%)	Compare
STIM Neuronetics, Inc.	$148.6M	— (loss-making)	— (loss-making)	+9.08% (above 0%: growing)	n/m	+62.06% (above 0%: growing)	51.06%	(3.61%)	Compare
QTRX Quanterix Corporation	$145.2M	— (loss-making)	— (loss-making)	+34.44% (above 0%: growing)	n/m	+18.92% (above 0%: growing)	38.52%	(150.22%)
MXCT MaxCyte, Inc.	$134.2M	— (loss-making)	— (loss-making)	−14.53% (below 0%: shrinking)	n/m	+54.74% (above 0%: growing)	76.96%	(140.72%)	Compare
OWLT Owlet, Inc.	$129.8M	— (loss-making)	— (loss-making)	+29.94% (above 0%: growing)	n/m	+55.74% (above 0%: growing)	64.44%	5.14%	Compare
APYX Apyx Medical Corporation	$107.8M	— (loss-making)	— (loss-making)	+22.08% (above 0%: growing)	n/m	−137.38% (below 0%: shrinking)	63.89%	(13.01%)	Compare
LUCD Lucid Diagnostics Inc.	$105.7M	— (loss-making)	— (loss-making)	+26.74% (above 0%: growing)	n/m	−7.04% (below 0%: shrinking)	1.97%	(868.45%)	Compare
ZOMDF Zomedica Corp.	$95.4M	— (loss-making)	— (loss-making)	+36.59% (above 0%: growing)	n/m	+40.48% (above 0%: growing)	63.51%	(42.92%)	Compare
Median of peers	$132.0M	—	—	+15.58%	—	+16.72%	63.70%	(26.91%)

All 149 Medical Devices stocks →

Quanterix Corporation (QTRX) key facts

Strength: Quanterix Corporation’s revenue for fiscal 2025 (year ended December 2025) was $138.9 million, up 1.07% from fiscal 2024.
Quanterix Corporation (QTRX) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, QTRX traded at $2.87, a market capitalization of $145.2 million.
Return on equity was −34.3% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −0.87 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.